Evidence map›Paper›PMID 35997126›Full record

ArticleCancer2022

Disparities in curative treatments and outcomes for early stage intrahepatic cholangiocarcinoma in the United States.

Yi-Te Lee, Amit G Singal, Marie Lauzon, Vatche G Agopian, Michael Luu, Mazen Noureddin, Tsuyoshi Todo, Irene K Kim, Marc L Friedman, Kambiz Kosari and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Racial and Ethnic Disparities in Survival among Patients with Cholangiocarcinoma in the United States: A Systematic Review and Meta-analysis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Pooled it
  2. Article
  3. Present and future of liver transplantation for cholangiocellular carcinoma: moving toward personalized multiparametric transplantability patterns.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Survival Benefit Relative to Treatment Modalities Among Patients with Very Early Intrahepatic Cholangiocarcinoma: an Analysis of the National Cancer Database.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Yi-Te LeeCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, California, USA.
Amit G SingalDivision of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0002-1172-3971
Marie LauzonBiostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Vatche G AgopianDepartment of Surgery, University of California, Los Angeles, Los Angeles, California, USA.
Michael LuuBiostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Mazen NoureddinKarsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Tsuyoshi TodoComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Irene K KimComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Marc L FriedmanDepartment of Radiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Kambiz KosariComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Nicholas N NissenComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Lewis R RobertsDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Julie K HeimbachDivision of Transplant Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Gregory J GoresDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Ju Dong YangKarsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.ORCID 0000-0001-7834-9825
Cedars-Sinai Medical Center · USMayo Clinic · USCalifornia NanoSystems Institute · USThe University of Texas Southwestern Medical Center · USUniversity of California, Los Angeles · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinomaR01MD012565 · NIMHD · UT SOUTHWESTERN MEDICAL CENTER · PI SINGAL, AMIT, YOPP, ADAM · 2018 to 2022
$4.3M
NCI NIH HHS P30 CA015083NIMHD NIH HHS R01 MD012565
6 · The paper itself

Abstract

backgroundCurative surgical treatments afford the best prognosis for patients with intrahepatic cholangiocarcinoma (iCCA); however, the comparative effectiveness of treatment options and factors associated with curative treatment receipt for early stage iCCA remain unknown.

methodsThe authors identified patients who were diagnosed with early stage iCCA, defined as a unifocal tumor <3 cm, during 2004-2018 from the National Cancer Database. Multivariable logistic and Cox regression analyses were used to identify the factors associated with curative treatment and overall survival (OS), respectively.

resultsThe proportion of patients with early stage iCCA increased from 4.5% in 2004 to 7.3% in 2018, with the odds of early stage detection increasing by 3.1% per year (odds ratio [OR], 1.031; 95% CI, 1.015-1.049). Of 1093 patients who had early stage iCCA, 464 (42.5%) underwent resection, 113 (10.3%) underwent ablation, 62 (5.7%) underwent liver transplantation, and 454 (41.5%) received noncurative treatments. Hispanic patients (adjusted OR [aOR], 0.57; 95% CI, 0.33-0.97) and Black patients (aOR, 0.47; 95% CI, 0.28-0.77) were less likely to receive curative treatments than White patients. Compared with patients who underwent surgical resection, those who underwent liver transplantation had a trend toward improved OS (adjusted hazard ratio [aHR], 0.63; 95% CI, 0.37-1.08), whereas those who underwent local ablation (aHR, 1.39; 95% CI, 1.01-1.92) and noncurative treatments (aHR, 3.97; 95% CI, 3.24-4.88) experienced worse OS.

conclusionsMore than one third of patients with early stage iCCA did not receive curative treatment, with Hispanic and Black patients being less likely to receive curative treatments than White patients. Surgical resection and liver transplantation were associated with improved survival compared with local ablation. Future studies should investigate disparities in curative treatment receipt and outcomes for early stage iCCA.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaBile Ducts, IntrahepaticEarly Detection of CancerHumansPrognosisUnited Statescomparative effectiveness researchcurative treatmentepidemiologyintrahepatic cholangiocarcinomaliver cancer

Identifiers

PMID35997126
PMCPMC9530023
OpenAlexW4292695864

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.